Skip To Main Content
Lilly
Menu closed
Lilly
  • Medical Home
    • Medical Information
Chat Click to chat
Question Submit a question

Information Request

Lilly Rep Request

Expand contact lilly
Lilly

You are now leaving the Lilly Medical Web site

The link you clicked on will take you to a site maintained by a third party, which is solely responsible for its content. Eli Lilly and Company does not control, influence, or endorse this site, and the opinions, claims or comments expressed on this site should not be attributed to Eli Lilly and Company. Eli Lilly and Company is not responsible for the privacy policy of any third party web sites. We encourage you to read the privacy policy of every web site you visit.

  1. Medical Information Right
  2. Verzenios ® ▼ (abemaciclib) Right
  3. How do I manage the Verzenios® (abemaciclib) side effect diarrhoea?
Search abemaciclib information
Search Medical Information


Tips for searching:

• You have to select a product and type at least 2 words to activate the search
• Use only words that are specific to the information you are looking for
• Avoid typing questions or sentences

Please do not use this field to report adverse events or product complaints. Adverse events and product complaints should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow card in the Google play or Apple app store. Adverse events and product complaints should also be reported to Lilly: please call Lilly UK on 01256 315 000.

Verzenios ® ▼ (abemaciclib)

This information is intended for UK registered healthcare professionals only as a scientific exchange in response to your search for information. For current prescribing information for all Lilly products, including Summaries of Product Characteristics, Patient Information Leaflets and Instructions for Use, please visit: www.medicines.org.uk (England, Scotland, Wales) or www.emcmedicines.com/en-GB/northernireland/ (Northern Ireland).

How do I manage the Verzenios® (abemaciclib) side effect diarrhoea?

At the first sign of loose stools, start treatment with anti-diarrhoeal agents such as loperamide and increase oral liquids. Dose modifications are recommended in patients who develop ≥ Grade 2 diarrhoea.

UK_cFAQ_ABE025_DIARRHOEA_MANAGEMENT
UK_cFAQ_ABE025_DIARRHOEA_MANAGEMENT
en-GB

Dose Modification and Management of Diarrhoea

Please find recommendations for dose modifications to manage diarrhoea presented in Management recommendations for diarrhoea  . 

Management recommendations for diarrhoea1,2  

The infographic illustrates how to manage diarrhoea with abemaciclib depending on Grade.

Monitoring of Patients with Diarrhoea

Monitor patients who take abemaciclib and treat diarrhoea if and when it occurs. It is not necessary to give patients prophylactic antidiarrhoeal medications.3,4

In severe diarrhoea, consider measuring neutrophil counts and body temperature. 

Give broad-spectrum antibiotics, like fluoroquinolones, to patients who require intravenous hydration or who have diarrhoea with neutropenia or fever.4

Carefully monitor and provide intravenois (IV) hydration and electrolyte replacement to patients who 

  • experience severe diarrhoea, or
  • experience any grade of diarrhoea with severe nausea or vomiting.4

Incidence and Duration of Diarrhoea in Clinical Studies

Diarrhoea is the most common adverse reaction. 85% of patients taking abemaciclib combined with endocrine therapy in the phase-3-clinical trials reported it.1

Most patients develop diarrhoea in the first month of treatment. The number decreased in the following months.1

Across clinical studies, the median time to onset of the first diarrhoea event was approximately 6 to 8 days, and the median duration of diarrhoea was

  • 7 to 12 days (Grade 2), and
  • 5 to 8 days (Grade 3).1

Diarrhoea returned to baseline or a lesser grade with supportive treatment such as loperamide or dose adjustment, or both.1

References

1Verzenios [summary of product characteristics]. Eli Lilly Nederland B.V., The Netherlands.

2US Department of Health and Human Services; National Institutes of Health and National Cancer Institute. Common terminology criteria for adverse events (CTCAE). Version 4.03. May 28, 2009. Updated June 14, 2010. Accessed April 28, 2020. https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf

3Hurvitz S, Martin M, Fernández Abad M, et al. Biological effects of abemaciclib in a phase 2 neoadjuvant study for postmenopausal patients with HR+, HER2- breast cancer. Cancer Res. 2017;77(4 suppl):S4-06. http://dx.doi.org/10.1158/1538-7445.SABCS16-S4-06.

4Data on file, Eli Lilly and Company and/or one of its subsidiaries.

Date of Last Review: 29 March 2021

Are you satisfied with this content?

Can't find what you're looking for? Contact us for answers to your medical questions.

  • Copyright
  • Terms and conditions
  • Privacy Policy & Cookies
  • Accessibility Information
  • Cookie settings

    MI-LM-UK-1005 Jul-2023 | ® Registered Trademark of Eli Lilly and Company | © Eli Lilly and Company 2023.

    This site is published by Eli Lilly and Company Ltd and is intended for Healthcare Professionals in the United Kingdom

    Lilly